Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors

2014132 citationsJournal Article

Authors

Ebrahim S. Delpassand · Erasmus University Rotterdam

Amin Samarghandi · Excel Diagnostics Imaging

Sara Zamanian · Cedars-Sinai Medical Center

Edward M. Wolin · Cedars-Sinai Medical Center

Mohammadali Hamiditabar · Excel Diagnostics Imaging

Gregory D. Espenan · Erasmus MC

Jack L. Erion

Abstract

Treatment with multiple cycles of (177)Lu-DOTATATE peptide receptor radionuclide therapy is well tolerated. This treatment results in control of the disease in most patients, whereas systemic toxicities are limited and reversible. Quality of life is also improved.

Topics & Keywords

Neuroendocrine Tumor Research Advances Neuroblastoma Research and Treatments Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Pancreas

Volume 43, Issue 4, pp. 518-525

DOI: 10.1097/mpa.0000000000000113

Field-Weighted Citation Impact: 8.82